Qiagen N.V. $QGEN Holdings Raised by State Street Corp

Key Points

• State Street increased its Qiagen stake by 4.5% in the second quarter, bringing its holdings to 2.18 million shares valued at approximately $85.4 million. Institutional investors collectively own 70% of the company.
• Qiagen exceeded quarterly expectations, reporting adjusted EPS of $0.62 versus the $0.60 consensus and revenue of $535.0 million versus estimates of $527.5 million. The company maintained fiscal 2026 EPS guidance of $2.43.
• Shares opened at $44.57, up 2%, while analyst sentiment remained mixed: the stock has an average “Hold” rating and a consensus price target of $43.51, below the current share price.

State Street Corp lifted its stake in Qiagen N.V. (NYSE:QGEN - Free Report) by 4.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,183,206 shares of the company's stock after acquiring an additional 93,575 shares during the quarter. State Street Corp owned 1.06% of Qiagen worth $85,363,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Manchester Capital Management LLC acquired a new position in Qiagen during the fourth quarter worth $42,000. Hilltop National Bank purchased a new position in shares of Qiagen during the second quarter worth $50,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Qiagen in the second quarter valued at $59,000. Allworth Financial LP grew its stake in shares of Qiagen by 20.8% in the second quarter. Allworth Financial LP now owns 1,841 shares of the company's stock valued at $72,000 after buying an additional 317 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Qiagen by 46.8% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,746 shares of the company's stock valued at $110,000 after buying an additional 876 shares during the period. Institutional investors and hedge funds own 70.00% of the company's stock.

Qiagen Stock Up 2.0%

Qiagen stock opened at $44.57 on Friday. The firm has a market capitalization of $9.19 billion, a P/E ratio of 22.84, a P/E/G ratio of 4.35 and a beta of 0.63. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48. Qiagen N.V. has a twelve month low of $32.53 and a twelve month high of $57.81. The stock's fifty day simple moving average is $42.73 and its 200-day simple moving average is $39.86.

Qiagen (NYSE:QGEN - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%.The firm had revenue of $535.04 million during the quarter, compared to analyst estimates of $527.50 million. During the same period last year, the business posted $0.60 earnings per share. Qiagen's revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, equities analysts expect that Qiagen N.V. will post 2.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

QGEN has been the topic of several research reports. Berenberg Bank set a $45.50 target price on Qiagen and gave the stock a "hold" rating in a research note on Tuesday, July 14th. JPMorgan Chase & Co. lifted their target price on Qiagen from $45.00 to $50.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. Citigroup reiterated a "neutral" rating and set a $45.00 price target (up from $38.00) on shares of Qiagen in a research note on Monday, August 10th. Morgan Stanley reissued an "overweight" rating on shares of Qiagen in a research report on Friday, September 11th. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $48.00 price objective on shares of Qiagen in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $43.51.

Qiagen Profile

QIAGEN N.V. is a global provider of sample preparation, molecular testing and bioinformatics solutions used in life sciences research, molecular diagnostics and applied testing. The company develops technologies that help customers isolate and analyze DNA, RNA and other biological materials from blood, tissue and other samples.

Its offerings include laboratory instruments, consumables, assay kits and software. Key product areas include automated sample-processing systems, polymerase chain reaction (PCR) and digital PCR solutions, next-generation sequencing workflows, bioinformatics tools, and diagnostic tests such as QuantiFERON for tuberculosis testing and QIAstat-Dx for syndromic testing.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.